Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, January 27, 2015
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Illumina Announces First Targeted NGS Solution for Forensic Genomics
Thursday, January 22, 2015
MiSeq FGx™ forensic genomics system brings sample-to-answer sequencing to forensic laboratories.

4.0 Release of Partek Flow Data Analysis Software
Thursday, January 22, 2015
Align, analyze, and visualize next generation sequencing data in users browser.

SYGNIS Announces the Global Launch of TruePrime™ Single Cell WGA Kit
Wednesday, January 21, 2015
First product launched for single cell DNA amplification.

Illumina Expands World’s Most Comprehensive Next-Generation Sequencing Portfolio
Tuesday, January 13, 2015
New systems extend access to production-scale sequencing.

Bioo Scientific Releases 18S ITS rRNA Library Prep Kit
Saturday, January 10, 2015
The NEXTflex™ 18S ITS Amplicon-Seq kit simplify eukaryotic metagenomic studies.

One Lambda's New RUO NXType Kit Available
Thursday, December 04, 2014
The new kit is a complete solution for HLA typing by NGS.

SYGNIS Presents its First Own Product Line: TruePrime™
Tuesday, December 02, 2014
TruePrime™ revolutionizes whole genome and transcriptome amplification.

OSU Launches NGS Cancer Panels Using GO Clinical Workbench
Friday, November 28, 2014
Company’s GO Clinical Workbench™ to enable clinical reporting of mutations detected from NGS.

Verifying the Quality and Quantity of your ChIP DNA
Tuesday, November 25, 2014
Porvair Sciences has published a new guide to help laboratories choose the best way to verify the quality and quantity of their Chromatin Immunoprecipitation (ChIP) DNA.

<< 1 2 3 4 5 6 7 >>
Showing Results 1 - 10 of 228
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn